Loading, please wait...
Please join us for the second Resident Seminar of the 2023-24 Series. Presented by PGY1 and PGY2 residents from the St. Louis area, these sessions focus on current therapeutic topics in the practice of pharmacy.
Sessions will be held live in the Academic & Research Building (ARB) third and fourth floor classrooms and virtually via Microsft Teams.
Pharmacists may earn 0.75 contact hour of CPE credit per session (maximum 2.25 contact hours for 3 sessions). To receive CPE credit, the evaluation must be completed for each activity attended.
REGISTRATION & PARKING: FREE
Complete the Advance Registration & Parking Form by no later than November 6 if you plan to attend in person and park in the UHSP Main Garage (4531 Nash Way, St. Louis, MO 63110). Registration is not needed for those planning to attend via the Microsot Teams links.
- ARB 336: Click here to join via Microsoft Teams
- ARB 354: Click here to join via Microsoft Teams
- ARB 355: Click here to join via Microsoft Teams
- ARB 406: Click here to join via Microsoft Teams
- ARB 470: Click here to join via Microsoft Teams
HANDOUTS: Participants attending in-person will be provided paper copies of handouts within the classrooms. Virtual attendees can access the handouts in the conversation feature within Teams.
ATTENDANCE & EVALUATION: Attendance will be collected for both in-person and live participants. To receive CPE credit, pharmacists must complete the evaluation for each activity attended (maximum 2.25 contact hours for 3 sessions). The evaluation link will close on November 15; CPE credit may no longer be claimed after that time. CPE credit will not be corrected or awarded if more than 60 days have passed from the event.
ATTENDANCE & EVALUATION: Attendance will be collected for both in-person and live participants. To receive CPE credit, pharmacists must complete the evaluation for each activity attended (maximum 2.25 contact hours for 3 sessions). The evaluation link will close on November 15; CPE credit may no longer be claimed after that time. CPE credit will not be corrected or awarded if more than 60 days have passed from the event.
SPECIAL ACCOMMODATIONS
Attendees of all abilities are welcome to participate. If you will require accommodations, please notify ce@uhsp.edu
Date: Nov 8, 2023 01:00 PM - 03:35 PM
Fee
$0.00
CE Hours
10.50
Activity Type
- Knowledge
Antifibrotics are the mainstay of therapy in fibrotic interstitial lung diseases and serve as the best pharmacologic treatment option available. While they slow disease progression, the only curative treatment remains to be lung transplantation. Due to the mechanism of antifibrotics, there is concern for poor outcomes when antifibrotics are used in the perioperative period of lung transplant. However, it is challenging to determine if or when to discontinue therapy prior to lung transplant, as organ wait list times can be variable. The goal of the presentation is to describe the treatment of interstitial lung disease and evaluate appropriate indications for antifibrotic discontinuation in the pre-lung transplant period. This presentation will review pathophysiology and current management strategies, as well as summarize literature pertaining to antifibrotic use in the period of lung transplantation.
Objectives
- Describe the pathophysiology and treatment of interstitial lung disease
- Summarize literature on antifibrotic use in the peri-operative lung transplant period
- Evaluate considerations for discontinuation of antifibrotics prior to lung transplant
Speaker(s)/Author(s)
|
Alisar Aljundi, PharmD |
Activity Number
0033-0000-23-019-L01-P
Date:
11/08/23
Time:
02:50 PM - 03:35 PM
CE Hours
0.75
Bispecific T-cell engagers, Glofitamab and Epcoritamab, are a newly FDA-approved treatments for relapse/refractory diffuse large B-cell lymphoma (R/R DLBCL). As a new immunotherapy for DLBCL, there are unique mechanisms of action, premedication, dosing, side effects, and logistical considerations which pharmacists should be provided education.
This CE activity seeks to provide a clinical approach to management of relapse/refractory diffuse large B-cell lymphoma. This presentation will evaluate available literature supporting the use of bispecific T-cell engagers in this DLBCL setting.
Objectives
- Explain current treatment landscape of DLBCL
- Describe treatment outcomes of relapsed/refractory DLBCL
- Identify differences between current FDA approved bispecific T-cell engagers for DLBCL
Speaker(s)/Author(s)
|
Alan Catalano, PharmD |
Activity Number
0033-0000-23-022-L01-P
Date:
11/08/23
Time:
01:00 PM - 01:45 PM
CE Hours
0.75
Triple antithrombotic therapy defined as two antiplatelet agents along with an anticoagulant, is an area of much discussion and consideration for patients undergoing percutaneous coronary intervention with a past medical history of atrial fibrillation. The use of triple therapy increases the overall risk of bleeding whilst trying to balance the risk of ischemic events. Recent studies have emerged regarding the use of dual therapy (antiplatelet plus anticoagulant) versus triple therapy for this unique population to assess the efficacy between the two treatment regimens. Evidence and literature will be evaluated to discern the role for triple therapy in this population and its duration considering unique factors and de-escalation strategies.
Objectives
- Compare and contrast mechanisms of action for anticoagulants and antiplatelets.
- Identify the appropriate antithrombotic treatment regimen and duration for a patient with atrial fibrillation undergoing percutaneous coronary intervention.
Speaker(s)/Author(s)
|
Angus Owan, PharmD |
Activity Number
0033-0000-23-020-L01-P
Date:
11/08/23
Time:
02:50 PM - 03:35 PM
CE Hours
0.75
Research in MDMA assisted therapy for severe Post-Traumatic Stress Disorder treatment has been growing in the past few years. This seminar aims to discuss the prevalence and symptoms of PTSD, identify the current recommendations for treatment of PTSD, evaluate current literature, and identify MDMA's place in therapy for management of PTSD
Objectives
- Discuss the prevalence and symptoms of Post-Traumatic Stress Disorder
- Identify the current recommendations for treatment of PTSD
- Describe 3,4 methylenedioxymethamphetamine’s place in therapy for management of PTSD
Speaker(s)/Author(s)
|
Dominique Vu, PharmD |
Activity Number
0033-0000-23-021-L01-P
Date:
11/08/23
Time:
01:55 PM - 02:40 PM
CE Hours
0.75
Current therapies for pulmonary arterial hypertension (PAH) are able to delay disease progression via targeting of the nitric oxide, endothelin-1, and prostacyclin pathways. Despite the availability of these treatments, morbidity and mortality rates remain elevated in PAH patients. In 2020, the Food and Drug Administration granted Breakthrough Therapy status to sotatercept, a fusion protein that serves as a ligand trap in the bone morphogenetic protein receptor type 2 pathway that is primarily associated with PAH. While Phase 2 and 3 trials for sotatercept examined its potential role as add-on therapy for PAH, the improvements in morbidity and mortality found in these trials may indicate its future use in early treatment of PAH. Clinical guidelines currently offer no guidance on the use of sotatercept in the setting of PAH. The presenter will review the available literature evaluating the role of sotatercept in the treatment of PAH.
Objectives
- Identify the primary physiologic pathways involved in the pathophysiology of pulmonary arterial hypertension (PAH)
- Describe the mechanism of action of sotatercept in the treatment of PAH
- Explain the role of sotatercept among current therapies for PAH
Speaker(s)/Author(s)
|
Emilee Thurman, PharmD |
Activity Number
0033-0000-23-023-L01-P
Date:
11/08/23
Time:
01:55 PM - 02:40 PM
CE Hours
0.75
This seminar presentation will review the prevalence, diagnosis, and guideline recommendations surrounding Clostridioides difficile infection (CDI), with a focus on recurrent infection. CDI pathophysiology and risk factors
will be discussed as they apply to CDI recurrence. The focus of the presentation will be to explore the role of pharmacotherapy in recurrence prevention, comparing current guideline recommendations and newly approved agents, Rebyota and Vowst.
will be discussed as they apply to CDI recurrence. The focus of the presentation will be to explore the role of pharmacotherapy in recurrence prevention, comparing current guideline recommendations and newly approved agents, Rebyota and Vowst.
Objectives
- Identify the risk factors contributing to recurring CDI.
- Compare and contrast prevention strategies - Bezlotoxumab, Rebyota, and Vowst
- Determine most appropriate preventative strategy given a patient case.?
Speaker(s)/Author(s)
|
Gabrielle Hahn, PharmD |
Activity Number
0033-0000-23-024-L01-P
Date:
11/08/23
Time:
01:55 PM - 02:40 PM
CE Hours
0.75
Roughly one-third of patients with heart failure have an iron deficiency or have been diagnosed with anemia. Anemia has is independently associated with the severity and mortality of heart failure, while iron deficiency has shown to decrease exercise capacity. Current guidelines define iron deficiency as a ferritin level of < 100ug/L OR 100-300ug/L when TSAT is < 20%, while anemia is not specifically defined. This presentation will summarize what current literature has found pertaining to the benefit of giving iron replacement to patients with heart failure and anemia. Additionally, this presentation will explore data regarding which iron dose, route, and frequency has shown to be most beneficial in this population.
Objectives
- Describe the difference in outcomes in congestive heart failure (CHF) patients with iron deficiency compared to CHF patients without iron deficiency.
- Determine if intravenous (IV) iron would benefit a patient exhibiting iron deficiency.
- Identify the best iron replacement product for a patient’s condition.
Activity Number
0033-0000-23-025-L01-P
Date:
11/08/23
Time:
01:55 PM - 02:40 PM
CE Hours
0.75
This presentation will review the impact of respiratory syncytial virus (RSV) illness and who are at risk of severe disease that can lead to hospitalizations, discuss the literature on the available preventative agents, and examine the recommendations around the recently approved RSV vaccines. The overall goal of presentation is provide a deeper understanding of the recommendations for the RSV preventative agents for implementation within clinical practice.
Objectives
- Describe the prevalence of RSV illness and the risk factors for severe RSV illness.
- Discuss the literature on the different available preventative therapies.
- Explain the Advisory Committee on Immunization Practices (ACIP) and the American College of Obstetricians and Gynecologist (ACOG) RSV vaccine recommendations.
Speaker(s)/Author(s)
|
Kerilynn Morgan, PharmD |
Activity Number
0033-0000-23-026-L01-P
Date:
11/08/23
Time:
01:00 PM - 01:45 PM
CE Hours
0.75
SGLT2 inhibitors have been proven to have both cardiovascular and renal benefits in patients. Recently, their indication has expanded to include heart failure in addition to type 2 diabetes. In this expanded patient population that may see benefit, diabetes is often a comorbidity. Patients with type 1 diabetes may benefit from SGLT2 inhibitors for both A1c control and improvement in cardiovascular/renal outcomes, but adverse effects are a limiting factor. Previously, SLGT2 inhibitors were approved for patients with T1DM in Europe, but approval was revoked due to concern for diabetic ketoacidosis (DKA). This presentation will review the literature that led to approval/disapproval of SGLT2 inhibitors in patients with T1DM in order to determine which patients may be candidates for SGLT2 inhibitor therapy.
Objectives
- Summarize the mechanism and utility of SGLT2 inhibitors.
- Describe type 1 diabetes epidemiology and pathophysiology.
- Identify key outcomes and conclusions of trials studying SGLT2-i utility in T1DM.
- Recognize the appropriate place in therapy for SGLTi in treating T1DM.
Speaker(s)/Author(s)
|
Megan Hull, PharmD |
Activity Number
0033-0000-23-027-L01-P
Date:
11/08/23
Time:
02:50 PM - 03:35 PM
CE Hours
0.75
A brief background on psilocybin will be provided to introduce the substance for those who may be unfamiliar with it. There will be a review of three disease states that have literature supporting the utilization of psilocybin (including TRD, AUD, and PTSD). This presentation will discuss current treatment centers and laws surrounding the use of the substance. Furthermore, it will highlight proposed protocol and the pharmacist’s role in the implementation of this new treatment. Finally, it will conclude with future directions and a potential timeline for approval in Missouri.
Objectives
- Explain how treatment with psilocybin may be advantageous for TRD, AUD, and PTSD
- Define the current laws in place in Missouri for the use of psilocybin
- Distinguish how pharmacists may play a role in treatment with psilocybin in the future
Speaker(s)/Author(s)
|
Melissa McBride, PharmD |
Activity Number
0033-0000-23-032-L01-P
Date:
11/08/23
Time:
01:00 PM - 01:45 PM
CE Hours
0.75
This seminar presentation will briefly cover the pathophysiology, assessment, and treatment of patients with chronic obstructive pulmonary disease (COPD). The pharmacology of COPD treatments (i.e., beta agonists) and beta blocker therapies will be discussed, as well as how they are clinically related. Literature involving patients with COPD and cardiovascular disease, specifically post-myocardial infarction (MI) and heart failure with reduced ejection fraction (HFrEF), will be evaluated for the safety and efficacy of beta blocker use in this patient population. The topic of cardioselectivity will also be addressed, and the data will be compiled and applied to develop an algorithm for use in pharmacy clinical practice.
The goal of this presentation is to emphasize that the practice of withholding beta blockers from patients with COPD and comorbid HFrEF or post-MI is not founded, especially considering that beta blockers reduce morbidity and mortality in these cardiovascular indications.
Objectives
- From a pathophysiologic standpoint, describe the mechanism of action of beta blockers and why they are underprescribed in patients with chronic obstructive pulmonary disease (COPD)
- Evaluate the risks and benefits of beta blocker therapy in a patient with COPD.
- Compare and contrast the data regarding cardioselective and noncardioselective beta blocker use in patients with COPD to make an informed and patient-specific recommendation
Speaker(s)/Author(s)
|
Meredith Meyer, PharmD |
Activity Number
0033-0000-23-028-L01-P
Date:
11/08/23
Time:
01:00 PM - 01:45 PM
CE Hours
0.75
Traumatic brain injuries (TBIs) occur whenever an injury disrupts baseline brain function; in pediatric patients, severe TBIs require acute, patient-centered care in order to optimize long-term outcomes. The pathophysiology of TBIs is complex, and it can be overwhelming for practitioners to develop a treatment plan centered to a patient's specific needs or clinical presentation. The pharmacotherapy portion of TBI management is especially complex in pediatric patients, as the majority of literature surrounding medication use in TBIs is limited to adult populations. The Guidelines for the Management of Pediatric Severe Traumatic Brain Injury were last updated in 2019. While these guidelines can be used as a framework for developing pharmacotherapy regimens, there are not strong recommendations for when to use certain medications, and the guidelines defer the decision to the practitioner. These guidelines, however, do not encompass publications after June 2017. The purpose of this seminar is to present guideline-directed pharmacotherapy recommendations for pediatric TBI management along with recent publications to construct an optimal treatment regimen. The presentation will focus on recommendations for hyperosmolar therapy, analgesia and sedation, seizure prophylaxis, corticosteroids, and high-dose barbiturate therapy.
Objectives
- Describe the pathophysiology and common etiologies of traumatic brain injury (TBI)?
- Identify the components commonly included in treatment plans for pediatric TBIs
- Implement appropriate pharmacotherapy choices based on a patient’s clinical presentation
Speaker(s)/Author(s)
|
Parker Lindsey, PharmD |
Activity Number
0033-0000-23-030-L01-P
Date:
11/08/23
Time:
01:55 PM - 02:40 PM
CE Hours
0.75
Postpartum depression (PPD) is a perinatal major depressive episode that specifically impacts females, leading to intense feelings of sadness, anxiety, fatigue, and exhaustion. This presentation will address the complexity of PPD pathophysiology, diagnosis, and available treatment options. Additionally, we will explore the mechanisms of action and therapeutic benefits of Brexanolone (Zulresso) and Zuranolone (Zurzuvae) for PPD treatment.The comprehensive analysis of the primary literature will help determine the clinical significance of available treatment options.
Furthermore, it will assess and compare the advantages of each therapy, impacts on PPD, potential cost savings, and overall benefits for females affected by PPD. After the presentation, pharmacists will gain a better understanding of the pathophysiology of PPD, will become familiar with available treatment options, and be equipped to apply knowledge in their practice effectively.
Objectives
- Discuss risk factors, etiology, and pathophysiology of postpartum depression (PPD)
- Discuss guidelines recommendations for PPD treatment
- Discuss clinical trials representing effectiveness and safety associated with the use of GABA- A Receptor Positive Modulators for PPD treatment
Speaker(s)/Author(s)
|
Tatsiana Maksimenka, PharmD |
Activity Number
0033-0000-23-029-L01-P
Date:
11/08/23
Time:
02:50 PM - 03:35 PM
CE Hours
0.75
While the utility of guideline directed medical therapy (GDMT) is well defined in patients with heart failure with reduced ejection fraction (HFrEF), it is uncertain whether there is a significant benefit in our patients with left ventricular assist devices (LVADs). Mechanically offloading the left ventricle with an LVAD can help to reduce ventricular remodeling with the complication of potential increase in right ventricular strain. Mechanistically, the use of neurohormonal blockade should help to offer a benefit to reduce this remodeling further. Additionally, there are some proposed additional benefits such as a reduction in implant arrhythmias with beta blockers or reduction in gastrointestinal bleeding with angiotensin receptor blockers. There is not a great deal of guidance as to when GDMT should be implemented and which, if any, should be prioritized in our patients with LVADs. This presentation aims to provide some guidance to our fellow pharmacists on which agents could be useful in these patients.
Objectives
- Compare and contrast GDMT medications and use in patients with LVADs.
- Describe potential risks and benefits of LVAD for bridging to transplant, destination therapy, or bridge to recovery
- Recommend appropriate GDMT agents for patients with LVADs
Speaker(s)/Author(s)
|
Tyler Fechte, PharmD |
Activity Number
0033-0000-23-031-L01-P
Date:
11/08/23
Time:
01:55 PM - 02:40 PM
CE Hours
0.75
